D.E. Shaw Research

D.E. Shaw Research is a private, computationally-driven drug discovery company that operates at the intersection of supercomputing, molecular dynamics, and machine learning. The company has built a unique, fully integrated platform combining proprietary hardware (Anton supercomputers) and software to simulate biological processes with unprecedented timescales and resolution. This enables the atomic-level design of novel therapeutics, resulting in a pipeline with seven clinical-stage drug candidates, three of which were designed independently. The company represents a highly specialized and capital-intensive approach to de-risking early-stage drug discovery through physics-based simulation.

Integrated platform combining special-purpose supercomputers (Anton) for millisecond-scale molecular dynamics simulations, advanced simulation software, and novel machine learning applications for atomic-level drug design and discovery.

DESRES competes with a range of computational drug discovery companies, including Schrödinger (public, software-focused), Relay Therapeutics (public, focused on protein dynamics), and numerous AI-native biotechs (e.g., Recursion, Exscientia). Its key differentiator is its proprietary, vertically integrated hardware-software stack, enabling uniquely long-timescale simulations not easily replicated by competitors relying on commercial cloud GPUs.